Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07225686 · ClinicalTrials.gov registry record · Phase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

A Phase 3 study of Obesity and Obstructive Sleep Apnea, sponsored by Amgen.

Recruiting
Registry status
Phase 3
Development phase
250
Enrollment target
20
Study locations

NCT07225686 is a Phase 3 study of Obesity and Obstructive Sleep Apnea that is actively recruiting participants, run by Amgen. The registered enrollment target is 250 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07225686, a Phase 3 study of Obesity and Obstructive Sleep Apnea, is actively recruiting participants, sponsored by Amgen.

RECRUITING
Registry status
Phase 3
Development phase
250 participants
Enrollment target
20
Study locations

Study Summary

This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are receiving positive airway pressure (PAP) therapy and are living with overweight or obesity.

Conditions Studied

Obesity Obstructive Sleep Apnea

Interventions

  • DRUG Placebo
  • DRUG Maridebart cafraglutide

Study Locations (20)

Other

  • Nemocnice Rudolfa a Stefanie Benesov as - Benesov U Prahy
  • Cerebrovaskularni poradna sro - Ostrava - Poruba
  • InnoDiab Forschung - Essen
  • Diabeteszentrum Hamburg West - Hamburg

Florida

  • Teradan Clinical Trials - Brandon
  • Destiny Research Center - Palmetto Bay
  • Clinical Research Center Of Florida - Pompano Beach

Texas

  • FutureSearch Trials of Neurology - Austin
  • Epic Medical Research - DeSoto - DeSoto
  • Sleep Therapy & Research Center - San Antonio

Ontario

  • Aggarwal and Associates Ltd - Brampton
  • Wharton Medical Clinic - Hamilton

California

  • Peninsula Research Associates - Rolling Hills Estates

New York

  • Basil Clinical - Laurelton

North Carolina

  • Monroe Biomedical Research - Monroe

Ohio

  • CTI Clinical Research Center - Cincinnati

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2025-12-19
Est. Completion 2028-09-13
Phase Phase 3

Sponsor

Amgen

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07225686

The ClinicalTrials.gov registry entry for NCT07225686 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (69% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07225686 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Florida, Texas.

Frequently Asked Questions

What is clinical trial NCT07225686 about?

NCT07225686 is a clinical study titled "Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy". This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are receiving positive airway pressure (PAP) therapy and are living with overweight or obesity.

What is the current status of trial NCT07225686?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2025-12-19. Estimated completion is 2028-09-13.

What conditions does trial NCT07225686 study?

This clinical trial studies the following conditions: Obesity, Obstructive Sleep Apnea.

What interventions are being tested in trial NCT07225686?

The interventions under investigation include: Placebo (DRUG), Maridebart cafraglutide (DRUG).

Who is sponsoring clinical trial NCT07225686?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07225686 being conducted?

This trial has 20 study locations across California, Florida, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Obstructive Sleep Apnea

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.